29 completed, 11 terminated, 4 withdrawn, 3 unknown. 51 Phase 2, 6 Phase 1, 3 Phase 3.
Follow Antithymocyte Globulin: new trials by email Literature Review of Antithymocyte Globulin trials Research Report on Antithymocyte Globulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TCD601 in de Novo Renal Transplant Recipients TCD601, belatacept, ATG - Renal Transplantation | Phase 2 | Completed | ITB-Med LLC | 76 | 2023-12-28 | 2026-05-05 |
| STOP-T1D Low-Dose (ATG) Antithymocyte Globulin, Placebo (for ATG) - Diabetes Mellitus, Type 1 | Phase 2 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 | 2023-11-01 | 2026-05-07 |
| Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy Romiplostim, Antithymocyte Globulin, Cyclosporine A - Severe Aplastic Anemia (SAA) | Phase 2 | Withdrawn | Amgen | 2023-08-31 | 2023-09-29 | |
| Selective CD28 Blockade in Renal Transplant Recipients Lulizumab, Tacrolimus, Thymoglobulin® - Kidney Transplantation, Renal Transplant Recipients | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-01-10 | 2023-03-22 | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation Antithymocyte Globulin - Haploidentical Hematopoietic Stem Cell Transplantation | Phase 2 | Unknown | Chinese PLA General Hospital | 63 | 2020-12-01 | 2023-04-11 |
| Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 16 | 2019-08-08 | 2026-06-11 |
| RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT Cytarabine - Acute Leukemia, Myelodysplastic Syndromes | Phase 2 | Unknown | Peking University People's Hospital | 50 | 2018-02-01 | 2024-03-26 |
| RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT Cytarabine - Myelodysplastic Syndromes | Phase 2 | Unknown | Peking University People's Hospital | 50 | 2018-02-01 | 2022-04-20 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin - Kidney Transplant, Type 1 Diabetes | Phase 2 | Completed | Massachusetts General Hospital | 2 | 2017-01-01 | 2023-12-22 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Thymoglobulin, Bortezomib, Tacrolimus - Acute Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Emory University | 5 | 2016-09-01 | 2018-04-30 |
| Personalized NK Cell Therapy in CBT Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2016-05-19 | 2026-11-02 |
| Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) living related donor partial liver transplantation, Total body irradiation, Bone marrow transplant from same donor - Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant) | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-03-01 | 2018-06-15 | |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil - Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Robert Lowsky | 18 | 2015-06-01 | 2021-06-24 |
| Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging - Leukemia, Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2013-01-01 | 2020-05-05 |
| Allogeneic Stem Cell Transplant for CLL Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2012-11-21 | 2020-02-24 |
| CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 27 | 2012-10-29 | 2024-07-23 |
| Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin - Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 64 | 2012-10-25 | 2025-02-28 |
| Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Anti-Thymocyte Globulin, Cyclosporine, Filgrastim - Aplastic Anemia, de Novo Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 140 | 2012-06-25 | 2026-06-22 |
Showing 20 of 51. Sign in to see all of them.
Myelodysplastic Syndromes (16) · Leukemia, Myeloid, Acute (9) · Hodgkin Disease (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Anemia, Aplastic (6) · Diabetes Mellitus, Type 1 (6) · Graft vs Host Disease (6) · Leukemia (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Hematologic Neoplasms (5) · Lymphoma (5) · Anemia, Refractory, with Excess of Blasts (4) · Myeloproliferative Disorders (4)
M.D. Anderson Cancer Center (20) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Fred Hutchinson Cancer Center (4) · Masonic Cancer Center, University of Minnesota (3) · Massachusetts General Hospital (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Peking University People's Hospital (2) · Amgen (1) · Children's Oncology Group (1) · Chinese PLA General Hospital (1) · Emory University (1) · ITB-Med LLC (1) · National Cancer Institute (NCI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institutes of Health Clinical Center (CC) (1)
United States (47) · China (3) · Australia (1) · Canada (1)
Issa Khouri (2) · Leona Holmberg (2) · Xiao-Jun Huang (2) · Ali Naji, MD, PhD (1) · Amanda Olson (1) · Amin Alousi, MD (1) · Amin M. Alousi, MD (1) · Andrew B. Adams, MD, PhD (1) · Andrew Posselt, MD, PhD (1) · Angela Smith, MD (1) · Bernhard Hering, MD (1) · Camillo Ricordi, MD (1) · Chitra Hosing (1) · Chitra M. Hosing, MD (1) · Christian P. Larsen, MD, DPhil (1)
PMID 20107229, PMID 20383216, PMID 20946966, PMID 23901089, PMID 24622416, PMID 26416896, PMID 27053235, PMID 27208317, PMID 28198767, PMID 31212080, PMID 33718234, PMID 37706580, PMID 39348419, PMID 39624016, PMID 39949947, PMID 40443407
P30CA015704 (2), P30CA016672 (2), P01CA049605 (1), R01CA211044 (1), U01AI138909 (1), U10CA031946 (1), U10CA180821 (1), UC4DK117009-01 (1)